These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28593995)

  • 1. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.
    Ali M; Kaltenbrun E; Anderson GR; Stephens SJ; Arena S; Bardelli A; Counter CM; Wood KC
    Nat Commun; 2017 Jun; 8():15617. PubMed ID: 28593995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
    Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
    Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
    Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
    Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
    Weinberg BA
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999
    [No Abstract]   [Full Text] [Related]  

  • 9. Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.
    Mason JD; Marks E; Fan SJ; McCormick K; Wilson C; Harris AL; Hamdy FC; Cunningham C; Goberdhan DCI
    J Extracell Vesicles; 2024 Jun; 13(6):e12465. PubMed ID: 38887984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
    Diaz LA; Williams RT; Wu J; Kinde I; Hecht JR; Berlin J; Allen B; Bozic I; Reiter JG; Nowak MA; Kinzler KW; Oliner KS; Vogelstein B
    Nature; 2012 Jun; 486(7404):537-40. PubMed ID: 22722843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer.
    Knickelbein K; Tong J; Chen D; Wang YJ; Misale S; Bardelli A; Yu J; Zhang L
    Oncogene; 2018 Aug; 37(33):4599-4610. PubMed ID: 29755130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
    Normanno N; Tejpar S; Morgillo F; De Luca A; Van Cutsem E; Ciardiello F
    Nat Rev Clin Oncol; 2009 Sep; 6(9):519-27. PubMed ID: 19636327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
    McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
    Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
    BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H; Liu Y; Wu K; Luo H; Cui L
    Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.